Clinical AI, drug discovery, devices, and regulatory approvals.
A binational study suggests that the link between maternal influenza during pregnancy and children's neuropsychiatric disorders largely disappears when siblings are compared, pointing to shared familial factors.
A new Democratic proposal would scrap the No Surprises Act's arbitration process, drawing praise from consumer advocates and fierce opposition from provider groups.
Four deaths among evenamide-treated patients have prompted FDA safety concerns and a continued U.S. enrollment hold in a phase III schizophrenia trial.
A Yale study suggests an FDA-approved epilepsy drug, delivered via hydrogel, may both ease pain and reverse cartilage damage in osteoarthritis.
A short resistance-training regimen in mice reduced visceral fat cell size and revived fat-burning pathways even though body weight stayed unchanged.
More hospitals face Medicare payment cuts under the readmissions program, with penalties now based partly on Medicare Advantage data.
The 2026 Nobel in medicine honored light-based neuron control, while a new study showed early vision restoration in some patients and all six science laureates were men.
The diagnostics and drug development startup will use genetic test data to guide pharma partnerships and spin out new biotech companies.
The investigation targets major research universities, threatening a key pipeline for international biomedical postdocs.
A journalist and her daughter set out to document the families and researchers behind an ultra-rare genetic condition, turning a diagnosis into a shared investigation.
A wave of retirements and a possible midterm wave could put many new Democratic faces on the committees that write U.S. health policy.
Despite curative drugs, U.S. hepatitis C cases remain stagnant while England and others cut infections sharply.
A 100% tariff on imported pharmaceuticals has left smaller biotech companies without clear guidance on exemptions, while large drugmakers are shielded.
A new HHS rule would pay hospitals less for discounted 340B drugs, lowering Medicare spending and patient coinsurance.
The startup is bypassing doctors and insurers to sell AI breast cancer risk predictions directly to patients, arguing the usual route would take too long.
Neil Carleton is working to move beyond 'age-agnostic' breast cancer care, from electronic health record nudges to understanding tumor biology in older patients.
The court-ordered reevaluation of the abortion pill will not conclude until next year, drawing criticism from abortion opponents.
A MedPage Today report highlights two cases where direct emails to insurance company leaders overturned denied care, though experts warn the tactic is not without risk.